Bloomberg reports people are trying unapproved, untested peptides hoping for sharper thinking and a competitive edge, fueling a fast-growing gray market.
Recap by typeshit. Post by @bloombergbusiness on Instagram.
The Form 483 cites microbial growth in a clean hood, reversed cleanroom air pressure and active ingredients marked for research use only. Check which pharmacy filled your vial.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
University of Washington, Stanford and PNNL researchers paired modeling with lab testing to cut peptide design work from days to hours. The work dates to a 2017 Science paper.
Trefis says investors are watching whether MariTide's vomiting rate lands in the mid-20s or lower. Amgen also dropped an early obesity drug, AMG 513.
Loading…